{"id":34990,"date":"2024-03-19T12:05:54","date_gmt":"2024-03-19T11:05:54","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=34990"},"modified":"2024-03-13T12:36:24","modified_gmt":"2024-03-13T11:36:24","slug":"schwere-nebenwirkungen-nach-gentherapie-mit-car-t-zellen-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/schwere-nebenwirkungen-nach-gentherapie-mit-car-t-zellen-cme","title":{"rendered":"Schwere Nebenwirkungen nach Gentherapie mit CAR-T-Zellen [CME]"},"content":{"rendered":"<p>In den letzten Jahren haben Gentherapien, die zu den sog. Arzneimitteln f\u00fcr neuartige Therapien (ATMP = \u201eAdvanced Therapy Medicinal Products\u201c) geh\u00f6ren, zunehmende Bedeutung erlangt, insbesondere f\u00fcr die Behandlung von Tumor- und Autoimmunerkrankungen , , , . Zu den ATMP geh\u00f6ren neben Gentherapeutika somatische Zelltherapeutika und biotechnologisch bearbeitete Gewebeprodukte, die heute auch bereits in Kombinationen (kombinierte [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In den letzten Jahren haben Gentherapien, die zu den sog. Arzneimitteln f\u00fcr neuartige Therapien (ATMP = \u201eAdvanced Therapy Medicinal Products\u201c) geh\u00f6ren, zunehmende Bedeutung erlangt, insbesondere f\u00fcr die Behandlung von Tumor- und Autoimmunerkrankungen , , , . Zu den ATMP geh\u00f6ren neben Gentherapeutika somatische Zelltherapeutika und biotechnologisch bearbeitete Gewebeprodukte, die heute auch bereits in Kombinationen (kombinierte [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5981,5982,5977,5979,5983,5980,256,5978],"class_list":["post-34990","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-axicabtagene-ciloleucel","tag-brexucabtagene-autoleucel","tag-car-t-zellen","tag-ciltacabtagene-autoleucel","tag-idecabtagene-vicleucel","tag-lisocabtagene-maraleucel","tag-nebenwirkungen","tag-tisagenlecleucel"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=34990"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34990\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=34990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=34990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=34990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}